AERAS  [to 30 Jun 2018]
No new digest content identified.
BMGF – Gates Foundation  [to 30 Jun 2018] Center/Press-Releases
JUNE 20, 2018
Plans for Third Building on Seattle Campus
SEATTLE, June 20, 2018 — The Bill & Melinda Gates Foundation announced plans to move forward with a third building at their headquarters located in downtown Seattle, across from Seattle Center and the historic Space Needle. The foundation plans to break ground on the new building in Fall of 2019 with completion in Spring of 2022.


Bill & Melinda Gates Medical Research Institute    [to 30 Jun 2018]
   The Bill & Melinda Gates Medical Research Institute is a non-profit research organization dedicated to combating diseases that impact the world’s poorest. We strive to combat inequities in health by accelerating progress in translational science to ensure life-saving products are available and accessible to everyone. We consider ourselves pioneers dedicated to uncovering radical solutions that will close the gap between cutting-edge scientific innovation and its application to challenges in global health.
No new digest content identified..


CARB-X   [to 30 Jun 2018]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 30 Jun 2018]
No new digest content identified.


EDCTP    [to 30 Jun 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.


Emory Vaccine Center    [to 30 Jun 2018]
No new digest content identified.


European Medicines Agency  [to 30 Jun 2018]
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018
Nine medicines recommended for approval, including the first two CAR-T cell therapies in the EU

First two CAR-T cell medicines recommended for approval in the European Union
Development of Kymriah and Yescarta supported through PRIME .
European Vaccine Initiative  [to 30 Jun 2018]
27 June 2018
Registration for EVI 20th Anniversary Symposium now open
On 20/21 November, EVI will celebrate its 20th anniversary with a symposium in Heidelberg, Germany. A draft agenda is now…
FDA [to 30 Jun 2018]
No new digest content identified.
Fondation Merieux  [to 30 Jun 2018]
Support for Laboratories
The Ministry of Public Health and Population launches Haiti’s first National Laboratory Policy
June 28, 2018 – Port-au-Prince (Haiti)
As part of the SPHaïtiLAB project, the Ministry of Public Health and Population (MSPP) launched the first National Laboratory Policy in Haiti on June 19th. The Minister of Health, Dr. Marie Gréta Roy Clément, presided over the ceremony that brought together the local and international partners involved in the project. The European Union, GHESKIO Centres and the Mérieux Foundation were among the partners who met in Port-au-Prince to present the key points, strategies and implementation of this policy…

Gavi [to 30 Jun 2018]
26 June 2018
Gavi supports rotavirus vaccine introduction in Uganda
The vaccine will help save the lives of thousands of children by combating the leading cause of severe diarrhoea.
Uganda, Buikwe – The Government of Uganda has launched today a new rotavirus vaccine to protect under five-year-old children from diarrhoea. The vaccine, which will be available for free in health facilities throughout the country, is the 11th vaccine to be added into the national schedule of the expanded programme on immunisation in Uganda. Rotavirus vaccine is safe and can be administered simultaneously with other routine infant vaccines. It is given orally and requires two doses at 6 and 10 weeks of age, with an interval of at least 4 weeks between doses…
GHIT Fund   [to 30 Jun 2018]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.


Global Fund [to 30 Jun 2018];&country=
No new digest content identified.


Hilleman Laboratories   [to 30 Jun 2018]
No new digest content identified.
Human Vaccines Project   [to 30 Jun 2018]
No new digest content identified.
IAVI  [to 30 Jun 2018]
No new digest content identified.
No new digest content identified.


IVAC  [to 30 Jun 2018]
No new digest content identified.
IVI   [to 30 Jun 2018]
WHO and IVI Hold Joint Symposium for MERS-CoV Vaccine Development in Seoul on June 26, 27
– 120 experts and professionals are updating progress in MERS human and dromedary camel vaccine development, seeking next steps
– Symposium co-hosted by WHO and convened as the 4th IVI Global Vaccine Forum sponsored by WHO, Seoul Cyber University, Korea Support Committee for IVI


JEE Alliance  [to 30 Jun 2018]
No new digest content identified.
MSF/Médecins Sans Frontières  [to 30 Jun 2018]
Report  27 June 2018
South Sudan
HIV Test and Treat pilot project in Yambio comes to a close
The Médecins Sans Frontières, Ministry of Health and the World Health Organization’s Test and Treat (T&T) HIV pilot project in Yambio county finished in June 2018.
The objective of the study was to assess feasibility and acceptability of the “treat all strategy” coupled with a community-based, patient-centred approach, based on HIV testing and same day antiretroviral treatment.
The report highlights the methodology used, the key learnings and the outcomes of the project.
The report found that bringing HIV testing and treatment closer to patients’ homes, with simplified protocols and less specialised health staff was feasible, resulting in comparable treatment outcomes to those of facility-based care.
NIH  [to 30 Jun 2018]
No new digest content identified.


PATH  [to 30 Jun 2018]
No new digest content identified.


Sabin Vaccine Institute  [to 30 Jun 2018]
No new digest content identified.
UNAIDS [to 30 Jun 2018]
Feature story
New UNAIDS web portal reinforces its commitment to accountability and transparency
27 June 2018
UNAIDS has launched a revamped transparency portal,, which presents current data on how UNAIDS is working to end AIDS as a public health threat by 2030.
The portal features joint results, country-level information, financial reporting, donor contributions, indicator trends and detailed information on the achievements of the UNAIDS Cosponsors.
“This portal is part of our collective efforts to ensure that we strengthen our transparency, accountability and communications around how we work and what we achieve. It provides Member States, donors, partners and staff alike with an excellent and highly accessible resource,” says Gunilla Carlsson, UNAIDS Deputy Executive Director…

UNAIDS Programme Coordinating Board opens
26 June 2018
The 42nd meeting of the UNAIDS Programme Coordinating Board (PCB) is taking place in Geneva, Switzerland, from 26 to 28 June…
Mr Sidibé also emphasized the need for a transformative approach to the epidemic that will include reforming laws and policies to end discrimination, expand community-led, people-centred approaches to HIV service delivery, the use of timely location–population data to inform decision-making, close the funding gap to achieve the Fast-Track Targets and reinforce the linkages between ending AIDS and achieving universal health coverage…


UNICEF  [to 30 Jun 2018]
Selected Press Releases/Reports
No new digest content identified…most recent press release dated 15 May 2018]

Vaccine Confidence Project  [to 30 Jun 2018]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 30 Jun 2018]
June 2018
Announcements: Vaccine safety references; vaccines and fevers 
::News & views – Best practices: Responding to vaccine deniers in public
Charlotte A. Moser, Assistant Director, and Paul A. Offit, Director, Vaccine Education Center at Children’s Hospital of Philadelphia
Wellcome Trust  [to 30 Jun 2018]
Published: 27 June 2018
New antibiotic approved for drug-resistant infections
A new antibiotic, developed with support from Wellcome, has been approved for patient use in the US.
The US Food and Drug Administration (FDA) has approved the use of plazomicin (opens in a new tab) (brand name ZEMDRI) for the treatment of complicated, drug-resistant urinary tract infections.
Wellcome supported development of the new medicine, including £8.1m funding for pre-clinical research and Phase 2 development.
The rapid rise and spread of untreatable superbugs is a serious and global health threat, currently killing around 700,000 people a year globally.
Tim Jinks, Head of Wellcome’s Drug-Resistant Infections Programme said: “This new antibiotic will be a vital last-resort treatment for patients with complicated and life-threatening urinary tract infections. As with any new antibiotic, ensuring appropriate use is essential…

The Wistar Institute   [to 30 Jun 2018]
No new digest content identified.


World Organisation for Animal Health (OIE)   [to 30 Jun 2018]
No new digest content identified.

BIO    [to 30 Jun 2018]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network  [to 30 Jun 2018]
No new digest content identified.

IFPMA   [to 30 Jun 2018]
No new digest content identified.

PhRMA    [to 30 Jun 2018]
No new digest content identified.